Chesley Taft & Associates LLC Increases Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Chesley Taft & Associates LLC increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,041 shares of the medical research company’s stock after buying an additional 582 shares during the quarter. Thermo Fisher Scientific comprises approximately 1.1% of Chesley Taft & Associates LLC’s investment portfolio, making the stock its 26th biggest holding. Chesley Taft & Associates LLC’s holdings in Thermo Fisher Scientific were worth $22,143,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Signature Resources Capital Management LLC lifted its position in Thermo Fisher Scientific by 318.2% during the second quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 35 shares during the period. Northwest Financial Advisors acquired a new position in Thermo Fisher Scientific during the fourth quarter valued at $29,000. True Wealth Design LLC lifted its position in Thermo Fisher Scientific by 1,275.0% during the fourth quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 51 shares during the period. LifeSteps Financial Inc. acquired a new position in shares of Thermo Fisher Scientific in the first quarter worth about $31,000. Finally, Headlands Technologies LLC acquired a new position in shares of Thermo Fisher Scientific in the first quarter worth about $32,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. TD Cowen upped their price objective on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. JPMorgan Chase & Co. upped their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Jefferies Financial Group restated a “buy” rating and set a $650.00 price target (up previously from $600.00) on shares of Thermo Fisher Scientific in a research report on Monday, June 3rd. Finally, HSBC upped their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Five investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $618.94.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 860 shares of the company’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $611.03, for a total value of $525,485.80. Following the transaction, the chief accounting officer now directly owns 1,814 shares in the company, valued at approximately $1,108,408.42. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 860 shares of the stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $611.03, for a total transaction of $525,485.80. Following the sale, the chief accounting officer now directly owns 1,814 shares in the company, valued at approximately $1,108,408.42. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at $70,238,340.48. The disclosure for this sale can be found here. In the last three months, insiders have sold 33,084 shares of company stock worth $19,767,092. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Trading Up 0.0 %

Shares of Thermo Fisher Scientific stock traded up $0.29 during mid-day trading on Friday, hitting $603.98. The stock had a trading volume of 1,076,197 shares, compared to its average volume of 1,714,754. The firm has a 50-day moving average of $570.86 and a two-hundred day moving average of $572.04. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $622.30. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. The firm has a market cap of $230.72 billion, a P/E ratio of 38.74, a price-to-earnings-growth ratio of 2.80 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, beating the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business had revenue of $10.54 billion during the quarter, compared to analysts’ expectations of $10.50 billion. During the same quarter in the prior year, the company posted $5.15 EPS. The business’s revenue for the quarter was down 1.4% on a year-over-year basis. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.71 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be issued a $0.39 dividend. The ex-dividend date is Friday, September 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.